Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro

Chemico-Biological Interactions

Volumn 192, Issue 3, 2011, Pages 220-232

  Fernand, Vivian E ^a   Losso, Jack N ^a   Truax, Robert E ^a   Villar, Emily E ^a   Bwambok, David K ^a   Fakayode, Sayo O ^b   Lowry, Mark ^a   Warner, Isiah M ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b WINSTON SALEM STATE UNIVERSITY   (United States)

Author keywords

Anthraquinones; Hypoxia tumor angiogenesis; Invasive breast cancer; Natural products; Non invasive breast cancer; Rhein

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VASCULOTROPIN 165;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MIGRATION INHIBITION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANTHRAQUINONES; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

SENNA ALATA;

EID: 79957644398     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2011.03.013     Document Type: Article

References (50)

1. A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer statistics, CA Cancer J. Clin. (2010), doi:10.1002/CAAC20073.
2. D. Coradini, M.G. Daidone, Biomolecular prognostic factors in breast cancer, Curr. Opin. Obstet. Gynecol. 16 (2004) 49-55. (Pubitemid 38241542)
3. K.C. Chu, R.E. Tarone, L.G. Kessler, L.A. Ries, B.F. Hankey, B.A. Miller, B.K. Edwards, Recent trends in US breast cancer incidence, survival, and mortality rates, J. Natl. Cancer Inst. 88 (1996) 1571-1579. (Pubitemid 26374510)
4. P. Vaupel, O. Thews, M. Hoeckel, Treatment resistance of solid tumors: role of hypoxia and anemia, Med. Oncol. 18 (2001) 243-259.
5. A.L. Harris, Hypoxia - a key regulatory factor in tumor growth, Nature Rev. Cancer 2 (2002) 38-47. (Pubitemid 37328806)
6. J. Folkman, Tumor angiogenesis: therapeutic implications, New Engl. J. Med. 285 (1971) 1182-1186.
7. J.D. Carpini, A.K. Karam, L. Montgomery, Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer, Angiogenesis 13 (2010) 43-58.
8. K. Lundgren, C. Holm, G. Landberg, Hypoxia and breast cancer: prognostic and therapeutic implications, Cell. Mol. Life Sci. 64 (2007) 3233-3247.
9. J.A. Forsythe, B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, G.L. Semenza, Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1, Mol. Cell. Biol. 16 (1996) 4604-4613. (Pubitemid 26272112)
10. G.L. Wang, B.-H. Jiang, E.A. Rue, G.L. Semenza, Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension, Proc. Natl. Acad. Sci. USA 92 (1995) 5510-5514.
11. P. Jaakkola, D.R. Mole, Y.-M. Tian, M.I. Wilson, J. Gielbert, S.J. Gaskell, A. von Kriegsheim, H.F. Hebestreit, M. Mukherji, C.J. Schofield, P.H. Maxwell, C.W. Pugh, P.J. Ratcliffe, Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation, Science 292 (2001) 468-472. (Pubitemid 32335942)
12. R. Bos, H. Zhong, C.F. Hanrahan, E.C. Mommers, G.L. Semenza, H.M. Pinedo, M.D. Abeloff, J.W. Simons, P.J. van Diest, E. van der Wall, Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis, J. Natl. Cancer Inst. 93 (2001) 309-314.
13. R. Bos, P. van der Groep, E. Greijer Astrid, A. Shvarts, S. Meijer, M. Pinedo Herbert, L. Semenza Gregg, J. van Diest Paul, E. van der Wall, Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma, Cancer 97 (2003) 1573-1581. (Pubitemid 36297788)
14. M.G. Rowlands, Y.M. Newbatt, C. Prodromou, L.H. Pearl, P. Workman, W. Aherne, High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity, Anal. Biochem. 327 (2004) 176-183.
15. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, W.L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (1987) 177-182. (Pubitemid 17231334)
16. H.R. Chang, Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer, Cancer 116 (2010) 2856-2867.
17. D.J. Newman, G.M. Cragg, Natural products as sources of new drugs over the last 25 years, J. Natl. Prod. 70 (2007) 461-477.
18. Y. Hasebe, K. Egawa, Y. Yamazaki, S. Kunimoto, Y. Hirai, Y. Ida, K. Nose, Specific inhibition of hypoxia-inducible factor (HIF)-1 alpha activation and of vascular endothelial growth factor (VEGF) production by flavonoids, Biol. Pharm. Bull. 26 (2003) 1379-1383. (Pubitemid 41685384)
19. J. Fang, C. Xia, Z. Cao, J.Z. Zheng, E. Reed, B.-H. Jiang, Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70s6K1 and HDM2/p53 pathways, Faseb. J. 19 (2005) 342-353. (Pubitemid 40316522)
20. C. Bocca, F. Bozzo, S. Cannito, S. Colombatto, A. Miglietta, CLA reduces breast cancer cell growth and invasion through ERα and PI3K/Akt pathway, Chem. Biol. Interact. 183 (2010) 187-193.
21. M. Shimizu, Y. Shirakami, H. Sakai, Y. Yasuda, M. Kubota, S. Adachi, H. Tsurumi, Y. Hara, H. Moiwaki, (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells, Chem. Biol. Interact. 185 (2010) 247-252.
22. V.E. Fernand, D.T. Dinh, S.J. Washington, S.O. Fakayode, J.N. Losso, R.O. van Ravenswaay, I.M. Warner, Determination of pharmacologically active compounds in root extracts of Cassia alata L. by use of high performance liquid chromatography, Talanta 74 (2008) 896-902.
23. H. Heyde, Medicinal Plants in Suriname (Medicijn Planten in Suriname), third ed., Stichting Gezondheidsplanten Informatie, Paramaribo, 1990.
24. C.M. Spencer, M.I. Wilde, Diacerein, Drugs 53 (1997) 98-106.
25. S. Franchi-Micheli, L. Lavacchi, C.A. Friedmann, L. Zilletti, The influence of rhein on biosynthesis of prostaglandin-like substances in-vitro, J. Pharm. Pharmacol. 35 (1982) 262-264.
26. R.H. Cichewicz, Y. Zhang, N.P. Seeram, M.G. Nair, Inhibition of human tumor cell proliferation by novel anthraquinones from daylilies, Life Sci. 74 (2004) 1791-1799. (Pubitemid 38117105)
27. T.C. Hsia, J.S. Yang, G.W. Chen, T.H. Chiu, H.F. Lu, M.D. Yang, F.S. Yu, K.C. Liu, K.C. Lai KC, C.C. Lin, J.G. Chung, The roles of endoplasmic reticulum stress and Ca2+ on rhein-induced apoptosis in A-549 human lung cancer cells, Anticancer Res. 29 (2009) 309-318.
28. W.W. Lai, J.S. Yang, K.C. Lai, C.L. Kuo, C.K. Hsu, C.K. Wang, C.Y. Chang, J.J. Lin, N.Y. Tang, P.Y. Chen, W.W. Huang, J.G. Chung, Rhein induced apoptosis through the endoplasmic reticulum stress, caspase- and mitochondria-dependent pathways in SCC-4 human tongue squamous cancer cells, In Vivo 23 (2009) 309-316.
29. A. Floridi, S. Castiglione, C. Bianchi, A. Mancin, Effect of rhein on the glucose metabolism of Ehrlich ascites tumor cells, Biochem. Pharmacol. 40 (1990) 217-222.
30. M. Chintalapati, R. Truax, R. Stout, R. Portier, J.N. Losso, In vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate, J. Agric. Food Chem. 57 (2009) 5201-5210.
31. P.L. Kuo, Y.L. Hsu, L.T. Ng, C.C. Lin, Rhein inhibits the growth and induces the apoptosis of Hep G2 cells, Planta Med. 70 (2004) 12-16. (Pubitemid 38233906)
32. P. Shi, Z. Huang, G. Chen, Rhein induces apoptosis and cell cycle arrest in human hepatocellular carcinoma BEL-7402 cells, Am. J Chin. Med. 36 (2008) 805-813.
33. P.A. Baeuerle, D. Baltimore, The physiology of the NF-kB transcription factor, in: P. Cohen, J.G. Foulkes (Eds.), Molecular Aspects of Cellular Regulation, vol. 6, Elsevier, Amsterdam, 1991, pp. 423-446.
34. F. Pacifico, A. Leonardi, NF-kB in solid tumors, Biochem. Pharmacol. 72 (2006) 1142-1152.
35. M.L. Lin, S.S. Chen, Y.C. Lu, R.Y. Liang, Y.T. Ho, C.Y. Yang, J.G. Chung, Rhein induces apoptosis through induction of endoplasmic reticulum stress and Ca2+dependent mitochondrial death pathway in human nasopharyngeal carcinoma cells, Anticancer Res. 27 (2007) 3313-3322.
36. Y.Y. Cheng, S.Y. Chiang, J.G. Lin, Y.S. Ma, C.L. Liao, S.W. Weng, T.Y. Lai, J.G. Chung, Emodin, aloe-emodin and rhein inhibit migration and invasion in human tongue cancer SCC-4 cells through the inhibition of gene expression of matrix metalloproteinase-9, Int. J. Oncol. 36 (2010) 1113-1120.
37. G. Aviello, I. Rowland, C.I. Gill, A.M. Acquaviva, F. Capasso, M. McCann, R. Capasso, A.A. Izzo, F.J. Borrelli, Anti-proliferative effect of rhein, an anthraquinone isolated from Cassia species, on Caco-2 human adenocarcinoma cells, J. Cell. Mol. Med. 14 (2010) 2006-2014.
38. B.D. Manning, L.C. Cantley, AKT/PKB signaling: navigating downstream, Cell 129 (2007) 1261-1274. (Pubitemid 46962095)
39. D.A. Murphy, S. Makonnen, W. Lassoued, M.D. Feldman, C. Carter, W.M. Lee, Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006), Am. J. Pathol. 169 (2006) 1875-1885. (Pubitemid 351182016)
40. G.D. Thakker, D.P. Hajjar, W.A. Muller, T.K. Rosengart, The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling, J. Biol. Chem. 274 (1999) 10002-10007.
41. A. Nakashio, N. Fujita, T. Tsuruo, Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway, Int. J. Cancer 98 (2002) 36-41. (Pubitemid 34113415)
42. H.K. Abbas, C.J. Mirocha, Isolation and purification of a hemorrhagic factor (wortmannin) from Fusarium oxysporum (N17B), Appl. Environ. Microbiol. 54 (1988) 1268-1274.
43. G.J. Downing, S. Kim, S. Nakanishi, K.J. Catt, T. Balla, Characterization of a soluble adrenal phosphatidylinositol 4-kinase reveals wortmannin sensitivity of type III phosphatidylinositol kinases, Biochemistry 35 (1996) 3587-3594. (Pubitemid 26092578)
44. Y. Lu, J. Zhang, J. Qian, The effect of emodin on VEGF receptors in human colon cancer cells, Cancer Biother. Radiopharm. 23 (2008) 222-228.
45. T. Kaneshiro, T. Morioka, M. Inamine, T. Kinjo, J. Arakaki, I. Chiba, N. Sunagawa, M. Suzui, N. Yoshimi, Anthraquinone derivative emodin inhibits tumor-associated angiogenesis through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation, Eur. J. Pharmacol. 553 (2006) 46-53.
46. E. Pozo-Guisado, A. Alvarez-Barrientos, S. Mulero-Navarro, B. Santiago-Josefat, P.M. Fernandez-Salguero, The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle, Biochem. Pharmacol. 64 (2002) 1375-1386.
47. A. Kamal, L. Thao, J. Sensintaffar, L. Zhang, M.F. Boehm, L.C. Fritz, F.J. Burrows, A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors, Nature 425 (2003) 407-410. (Pubitemid 37187270)
48. M. Hollingshead, M. Alley, A.M. Burger, S. Borgel, C. Pacula-Cox, H.H. Fiebig, E.A. Sausville, In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative, Cancer Chemother. Pharmacol. 56 (2005) 115-125.
49. J.Y. Jang, Y.K. Jeon, C.W. Kim, Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells, BMC Cancer 10 (2010) 391-400.
50. V. Wells, L. Mallucci, Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death, Breast Cancer Res. 11 (2009) R2, doi:10.1186/bcr2217.